JP2005523254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523254A5 JP2005523254A5 JP2003561595A JP2003561595A JP2005523254A5 JP 2005523254 A5 JP2005523254 A5 JP 2005523254A5 JP 2003561595 A JP2003561595 A JP 2003561595A JP 2003561595 A JP2003561595 A JP 2003561595A JP 2005523254 A5 JP2005523254 A5 JP 2005523254A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- alkyl
- aryl
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 36
- 229910052739 hydrogen Inorganic materials 0.000 description 27
- 239000001257 hydrogen Substances 0.000 description 27
- 150000002431 hydrogen Chemical class 0.000 description 24
- 125000004404 heteroalkyl group Chemical group 0.000 description 21
- 125000001072 heteroaryl group Chemical group 0.000 description 21
- 125000002252 acyl group Chemical group 0.000 description 20
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 20
- 125000003710 aryl alkyl group Chemical group 0.000 description 19
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 16
- 125000003282 alkyl amino group Chemical group 0.000 description 13
- 125000004663 dialkyl amino group Chemical group 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 12
- 125000000547 substituted alkyl group Chemical group 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 11
- 125000003107 substituted aryl group Chemical group 0.000 description 11
- 125000004442 acylamino group Chemical group 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 125000004043 oxo group Chemical group O=* 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 125000005415 substituted alkoxy group Chemical group 0.000 description 7
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 4
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- -1 carboxy, cyano, carbamoyl Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35148402P | 2002-01-22 | 2002-01-22 | |
| US60/351,484 | 2002-01-22 | ||
| US37375702P | 2002-04-17 | 2002-04-17 | |
| US60/373,757 | 2002-04-17 | ||
| PCT/US2003/001997 WO2003061651A1 (en) | 2002-01-22 | 2003-01-22 | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010006117A Division JP2010132672A (ja) | 2002-01-22 | 2010-01-14 | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005523254A JP2005523254A (ja) | 2005-08-04 |
| JP2005523254A5 true JP2005523254A5 (https=) | 2006-04-06 |
| JP4745609B2 JP4745609B2 (ja) | 2011-08-10 |
Family
ID=27616805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003561595A Expired - Fee Related JP4745609B2 (ja) | 2002-01-22 | 2003-01-22 | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
| JP2010006117A Pending JP2010132672A (ja) | 2002-01-22 | 2010-01-14 | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010006117A Pending JP2010132672A (ja) | 2002-01-22 | 2010-01-14 | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US6831093B2 (https=) |
| EP (1) | EP1467730A4 (https=) |
| JP (2) | JP4745609B2 (https=) |
| AU (1) | AU2003214879B2 (https=) |
| CA (1) | CA2473886C (https=) |
| WO (1) | WO2003061651A1 (https=) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2473886C (en) * | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| EP1496892B1 (en) * | 2002-04-11 | 2011-01-26 | Merck Sharp & Dohme Corp. | 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| EP1599201B1 (en) * | 2003-02-25 | 2010-04-14 | Merck Sharp & Dohme Corp. | Selective non-steroidal glucocorticoid receptor modulators |
| US20070088042A1 (en) | 2004-09-09 | 2007-04-19 | Meissner Robert S | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
| ATE447575T1 (de) | 2003-04-23 | 2009-11-15 | Merck & Co Inc | Selektive spirocyclische glucocorticoid-rezeptor- modulatoren |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| DE602004031356D1 (de) | 2003-11-21 | 2011-03-24 | Zalicus Inc | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen |
| AU2005222421B2 (en) * | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| US20060047855A1 (en) * | 2004-05-13 | 2006-03-02 | Microsoft Corporation | Efficient chunking algorithm |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| EP1841780B1 (en) | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| PE20061193A1 (es) | 2005-03-25 | 2006-12-02 | Glaxo Group Ltd | DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38 |
| MY145343A (en) | 2005-03-25 | 2012-01-31 | Glaxo Group Ltd | Novel compounds |
| US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| WO2007025303A2 (en) * | 2005-08-26 | 2007-03-01 | The Regents Of The University Of California | Non-steroidal antiandrogens |
| JP2009514969A (ja) | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | 医学的状態を治療するための方法、組成物、およびキット |
| PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
| MX2008013411A (es) | 2006-04-20 | 2008-11-04 | Glaxo Group Ltd | Nuevos compuestos. |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| MX2009004385A (es) | 2006-10-23 | 2009-05-22 | Merck & Co Inc | Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide. |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
| ES2383246T3 (es) | 2008-06-05 | 2012-06-19 | Glaxo Group Limited | 4-amino-indazoles |
| US20100092479A1 (en) * | 2008-08-18 | 2010-04-15 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| US7741350B1 (en) | 2009-01-28 | 2010-06-22 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
| EP2408458A1 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520684A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2411018A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012521760A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| AR076373A1 (es) | 2009-04-24 | 2011-06-08 | Glaxo Group Ltd | N-pirazolil carboxamidas como inhibidores de canales de calcio |
| LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体 |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| EP3020393B1 (en) | 2009-12-16 | 2020-10-07 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| CN101768608B (zh) * | 2009-12-31 | 2012-02-08 | 杭州师范大学 | 一种一锅法合成维兰德-米歇尔酮类化合物的方法 |
| WO2011087946A1 (en) * | 2010-01-15 | 2011-07-21 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| RS54286B1 (sr) | 2010-09-08 | 2016-02-29 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida |
| US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| EP2630127A1 (en) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| US9156791B2 (en) | 2010-10-21 | 2015-10-13 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| EP2683716A1 (en) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| RU2016112268A (ru) | 2013-10-17 | 2017-11-22 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Ингибитор PI3K для лечения респираторного заболевания |
| WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| FI3848027T3 (fi) | 2013-11-25 | 2023-05-04 | Corcept Therapeutics Inc | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita |
| WO2015148867A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| US20170100385A1 (en) | 2014-05-12 | 2017-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
| JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換されたヘテロアリール化合物および使用方法 |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| CA3055076C (en) | 2017-03-31 | 2022-02-22 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| CN111132964A (zh) * | 2017-04-11 | 2020-05-08 | 欧瑞克制药公司 | 糖皮质激素受体调节剂 |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| KR102737185B1 (ko) | 2018-01-20 | 2024-12-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 아미노피리미딘 화합물 및 이의 사용 방법 |
| FI3897589T3 (fi) | 2018-12-19 | 2026-01-13 | Corcept Therapeutics Inc | Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| PH12022551430A1 (en) | 2019-12-11 | 2023-11-20 | Corcept Therapeutics Inc | Methods of treating antipsychotic-induced weight gain with miricorilant |
| WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
| US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN113563163A (zh) * | 2021-07-07 | 2021-10-29 | 南京伊派森化学科技有限公司 | 一种5-溴-1，2，3-三甲氧基苯的合成方法 |
| IL319657A (en) | 2022-10-06 | 2025-05-01 | Corcept Therapeutics Inc | Glucocorticoid receptor modulator formulations |
| WO2024092195A1 (en) | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) * | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| NL273722A (https=) * | 1961-01-18 | |||
| DE1169442B (de) * | 1962-05-05 | 1964-05-06 | Schering Ag | Verfahren zur Herstellung von Steroidthioaethern bzw. Aminothiazolosteroiden |
| GB1071124A (en) * | 1965-05-11 | 1967-06-07 | Biorex Laboratories Ltd | Derivatives of pyrazolo-[4',5'-b]-11-oxo-18ª‡- and 18ª‰-olean-12-en-30-oic acid |
| US4412995A (en) | 1981-02-19 | 1983-11-01 | Sterling Drug Inc. | Pentacyclic phenylpyrazole compounds as anti-inflammatory agents |
| EP0102404A1 (en) * | 1982-09-02 | 1984-03-14 | Sterling Drug Inc. | Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof |
| CA1178965A (en) | 1982-09-13 | 1984-12-04 | Sterling Drug Inc. | Polycyclic fused pyrazole compounds useful as anti- inflammatory agents and preparation thereof |
| US6139873A (en) * | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
| JP2001518501A (ja) * | 1997-10-06 | 2001-10-16 | ビーエーエスエフ アクチェンゲゼルシャフト | インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体 |
| US6372779B1 (en) | 1997-12-29 | 2002-04-16 | Ortho Pharmaceutical Corporation | Anti-inflammatory compounds |
| US6380207B2 (en) | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
| ES2230880T3 (es) | 1998-07-30 | 2005-05-01 | Abbott Laboratories | Agentes selectivos anti-inflmatorios de glucocorticoides. |
| GB9816935D0 (en) | 1998-08-05 | 1998-09-30 | Karobio Ab | Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders |
| US6462036B1 (en) * | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
| DE60201921T2 (de) * | 2001-01-24 | 2005-10-06 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Kondensierte Pyrazolverbindungen |
| US7026484B2 (en) * | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| CN1578781A (zh) * | 2001-09-26 | 2005-02-09 | 拜尔药品公司 | 用作抗糖尿病药物的1,8－萘啶衍生物 |
| DE10164564B4 (de) * | 2001-12-14 | 2007-05-16 | Zentaris Gmbh | Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR) |
| CA2473886C (en) | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| EP1496892B1 (en) | 2002-04-11 | 2011-01-26 | Merck Sharp & Dohme Corp. | 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| JP3990718B2 (ja) * | 2003-01-09 | 2007-10-17 | ファイザー・インク | キナーゼ阻害剤としてのジアゼピノインドール誘導体 |
| CA2512987C (en) | 2003-01-21 | 2011-06-14 | Merck & Co., Inc. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| EP1599201B1 (en) * | 2003-02-25 | 2010-04-14 | Merck Sharp & Dohme Corp. | Selective non-steroidal glucocorticoid receptor modulators |
| ATE447575T1 (de) | 2003-04-23 | 2009-11-15 | Merck & Co Inc | Selektive spirocyclische glucocorticoid-rezeptor- modulatoren |
| US7071333B2 (en) * | 2003-07-30 | 2006-07-04 | Bristol-Myers Squibb Company | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2006124710A1 (en) | 2005-05-18 | 2006-11-23 | Merck & Co., Inc. | D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands |
| WO2007025303A2 (en) * | 2005-08-26 | 2007-03-01 | The Regents Of The University Of California | Non-steroidal antiandrogens |
-
2003
- 2003-01-22 CA CA2473886A patent/CA2473886C/en not_active Expired - Fee Related
- 2003-01-22 AU AU2003214879A patent/AU2003214879B2/en not_active Ceased
- 2003-01-22 EP EP03710722A patent/EP1467730A4/en not_active Withdrawn
- 2003-01-22 JP JP2003561595A patent/JP4745609B2/ja not_active Expired - Fee Related
- 2003-01-22 WO PCT/US2003/001997 patent/WO2003061651A1/en not_active Ceased
- 2003-01-22 US US10/350,260 patent/US6831093B2/en not_active Expired - Fee Related
-
2004
- 2004-10-22 US US10/972,250 patent/US7485660B2/en not_active Expired - Fee Related
-
2009
- 2009-02-03 US US12/365,106 patent/US7947726B2/en not_active Expired - Fee Related
-
2010
- 2010-01-14 JP JP2010006117A patent/JP2010132672A/ja active Pending
-
2011
- 2011-05-11 US US13/105,349 patent/US20110218225A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523254A5 (https=) | ||
| CA2473886A1 (en) | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof | |
| EP2928884B1 (de) | Neuartige benzimidazolderivate als ep4-antagonisten | |
| JP7033079B2 (ja) | 芳香族スルホンアミド誘導体 | |
| CN110256418B (zh) | 1，3-噻唑-2-基取代的苯甲酰胺 | |
| JP2007502287A5 (https=) | ||
| GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| JP2005506338A5 (https=) | ||
| WO2009009501A3 (en) | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | |
| JP2007502283A5 (https=) | ||
| WO2005103039A8 (en) | 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists | |
| EP1551803B8 (en) | Azabicyclo derivatives as muscarinic receptor antagonists | |
| JP2022538270A (ja) | ３－（５－メチル－１，３－チアゾール－２－イル）－ｎ－｛（１ｒ）－１－［２－（トリフルオロメチル）ピリミジン－５－イル］エチル｝ベンズアミドのアナログ | |
| CN115068468B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
| EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives | |
| JP2002526410A5 (https=) | ||
| JP2019524797A5 (https=) | ||
| JP2009506077A5 (https=) | ||
| JP2002530378A5 (https=) | ||
| JP2010521520A5 (https=) | ||
| WO2006035282A3 (en) | Muscarinic receptor antagonists | |
| WO2004093789A3 (en) | Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
| WO2007002764A3 (en) | Di-substituted oxadiazoles as cxc-chemokine receptor ligands | |
| JP2007504223A5 (https=) | ||
| WO2006018708A3 (en) | Pyrrolidine derivatives as muscarinic receptor antagonists |